Skip to Content
Merck
  • Adult onset cardiac dilatation in a transgenic mouse line with Galβ1,3GalNAc α2,3-sialyltransferase II (ST3Gal-II) transgenes: a new model for dilated cardiomyopathy.

Adult onset cardiac dilatation in a transgenic mouse line with Galβ1,3GalNAc α2,3-sialyltransferase II (ST3Gal-II) transgenes: a new model for dilated cardiomyopathy.

Proceedings of the Japan Academy. Series B, Physical and biological sciences (2011-10-12)
Osamu Suzuki, Takao Kanai, Toshio Nishikawa, Yoshie Yamamoto, Akira Noguchi, Kazuhiro Takimoto, Minako Koura, Yoko Noguchi, Kozue Uchio-Yamada, Shuichi Tsuji, Junichiro Matsuda
ABSTRACT

Sugar chain abnormalities in glycolipids and glycoproteins are associated with various diseases. Here, we report an adult onset cardiac dilatation in a transgenic mouse line with Galβ1,3GalNAc α2,3-sialyltransferase II (ST3Gal-II) transgenes. The transgenic hearts at the end-stage, at around 7 months old, were enlarged, with enlarged cavities and thin, low-tensile walls, typical of dilated cardiomyopathy. Although no apparent change was found in heart gangliosides, glycosylation of heart proteins was altered. Interestingly, sugar moieties not directly related to the ST3Gal-II catalytic reaction were also changed. Significant increases in calreticulin and calnexin were observed in hearts of the transgenic mice. These results suggest that expression of ST3Gal-II transgenes induces abnormal protein glycosylation, which disorganizes the endoplasmic/sarcoplasmic reticulum quality control system and elevates the calreticulin/calnexin level, resulting in suppression of cardiac function. The transgenic mice showed 100% incidence of adult onset cardiac dilatation, suggesting great potential as a new model for dilated cardiomyopathy.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
α-2,3-Sialyltransferase from Pasteurella multocida, recombinant, expressed in E. coli BL21, ≥2 units/mg protein